Results 221 to 230 of about 67,755 (267)

Angiogenesis is increased in B-cell chronic lymphocytic leukemia

Blood, 2001
Aguayo and colleagues recently reported elevated levels of vascular endothelial growth factor (VEGF) in the cells of B-cell chronic lymphocytic leukemia (CLL).[1][1] When discussing the possible significance of the elevated VEGF levels in CLL, the authors cite their prior abstract in which ...
LoAnn Peterson, Ameet R. Kini, Neil Kay
openaire   +2 more sources

Genetic Features of B‐Cell Chronic Lymphocytic Leukemia

Reviews in Clinical and Experimental Hematology, 2000
The genetic features of B‐cell chronic lymphocytic leukemia CLL) are currently being reassessed by molecular cytogenetic techniques such as fluorescence in situ hybridization FISH). Conventional cytogenetic studies by chromosome banding are difficult in CLL mainly because of the low in vitro mitotic activity of the tumor cells, which leads to poor ...
S, Stilgenbauer, P, Lichter, H, Döhner
openaire   +2 more sources

Stereotyped B-cell receptors in chronic lymphocytic leukemia

Leukemia & Lymphoma, 2014
Over the last decade, immunogenetic analysis of B-cell receptor immunoglobulins (BcR IGs) has proved to be a particularly fruitful field in chronic lymphocytic leukemia (CLL), not only for understanding disease pathogenesis but also for discriminating clinical subgroups with markedly distinct course and outcome.
Andreas, Agathangelidis, Anna, Vardi, Panagiotis, Baliakas, Kostas, Stamatopoulos   +3 more
openaire   +2 more sources

Targeting B Cell Signaling in Chronic Lymphocytic Leukemia

Current Oncology Reports, 2017
In recent years, a revolution in the management of chronic lymphocytic leukemia (CLL) has centered on the targeting of the B cell receptor (BCR) signaling pathway. Our improved understanding of the biology of cell signaling in CLL and the development of oral kinase inhibitors directed at the BCR pathway has led to the approval of two new agents and has
Jon E, Arnason, Jennifer R, Brown
openaire   +2 more sources

B-cell receptor signaling in chronic lymphocytic leukemia

Blood, 2011
AbstractThe B-cell receptor (BCR) is a key survival molecule for normal B cells and for most B-cell malignancies. Recombinatorial and mutational patterns in the clonal immunoglobulin (Ig) of chronic lymphocytic leukemia (CLL) have revealed 2 major IgMD-expressing subsets and an isotype-switched variant, each developing from distinct B-cell populations.
Stevenson, FK, Krysov, S, Davies, AJ, Steele, AJ, Packham, G   +4 more
openaire   +3 more sources

The cellular biology of B-cell chronic lymphocytic leukemia

Critical Reviews in Oncology/Hematology, 1998
In conclusion, B-CLL cells through their immunophenotype have the functional potential required to interact with cells in what has been called the immunological synapse, i.e. the cognate interactions between T-cells, antigen-presenting cells and B-cells during immunopoiesis.
openaire   +2 more sources

Trisomy 8 in B-cell chronic lymphocytic leukemia

Cancer Genetics and Cytogenetics, 2008
Association between trisomy 8 and myeloid disorders/malignancies has been well documented. We report on two patients with a known history of B-cell chronic lymphocytic leukemia (B-CLL) with bone marrow involvement. In addition to the classic B-CLL cytogenetic abnormalities in one of the patients, both showed a trisomy 8 clone in their bone marrow ...
Olga, Pozdnyakova, Dariusz, Stachurski, Lloyd, Hutchinson, Sapna, Ramakrishnan, Patricia Minehart, Miron   +4 more
openaire   +2 more sources

Myelomonocytic antigens in B-cell chronic lymphocytic leukemia

Leukemia Research, 1995
The clinical significance of myelomonocytic (MyMo) antigens in B-cell chronic lymphocytic leukemia (B-CLL) is unclear. We have analyzed the expression of MyMo antigens (CD13, CD14 (LeuM3, My4, Mo2), CD15, CD11b, CD11c, CD33 and CD68) on B-lymphocytes (CD19+) in 105 B-CLL patients and in 35 controls.
D, Tàssies, E, Montserrat, J C, Reverter, N, Villamor, M, Rovira, C, Rozman   +5 more
openaire   +2 more sources

Assessment of a B-cell function in chronic lymphocytic leukemia

Clinical Immunology and Immunopathology, 1976
Abstract Chronic lymphocytic leukemia (CLL) patients were tested for the numbers of T cells, B cells, and cells secreting immunoglobin (Ig) by recently developed methods with antibody coated erythrocytes. Five of seven patients had higher percentages (72–90%) of B cells and lower percentages (4–17%) of T cells than normal controls.
A J, Strelkauskas, W C, Eby, G A, Molinaro, S, Dray   +3 more
openaire   +2 more sources

p53 Mutations in B-Cell Chronic Lymphocytic Leukemia

1992
The p53 gene is a nuclear phosphoprotein that can function as a tumor suppressor gene (Michalovitz et al. 1991). Frequent mutations of the p53 gene have been detected in several types of solid tumors including breast (Mackay et al. 1988), colon (Vogelstein et al. 1989), lung (Yokota et al. 1987), liver carcinoma (Hsu et al. 1991), astrocytoma (Fults et
S, el Rouby, W, Bayona, S M, Pisharody, E W, Newcomb   +3 more
openaire   +2 more sources